Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Show more

Location: 40 Erie Street, Cambridge, MA, 02139, United States | Website: https://www.intelliatx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

1.153B

52 Wk Range

$5.90 - $24.16

Previous Close

$10.74

Open

$10.88

Volume

4,030,043

Day Range

$10.73 - $11.16

Enterprise Value

795.8M

Cash

459.7M

Avg Qtr Burn

-104.6M

Insider Ownership

4.80%

Institutional Own.

90.55%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
nexiguran ziclumeran (nex-z) (NTLA-2001) Details ATTR amyloidosis with polyneuropathy (ATTRv-PN)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002) Details Hereditary angioedema	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NTLA-3001 Details Alpha-1 Antitrypsin Deficiency, Lung disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
nexiguran ziclumeran (nex-z) (NTLA-2001) Details Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTQ923 / HIX763 (Hematopoietic Stem Cells (HSC)) Details Sickle cell disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NTLA-5001 Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.